Dr. Chi K. Tsang, MD

Dr. Tsang practices at Penn State Health Hampden Medical Center in Enola, Pennsylvania, part of Penn State.

Dr. Tsang's NPI, 1467457531, was assigned on June 16, 2005. Dr. Tsang graduated from Wayne State University School of Medicine in 1998. Dr. Tsang holds New York license 183205.

Dr. Tsang's primary practice is Penn State Health Hampden Medical Center, at 2200 Good Hope Road, Enola, PA 17025 in Cumberland County. The practice phone is (717) 981-9000.

Dr. Tsang's primary practice is Penn State Health Hampden Medical Center in Enola, Pennsylvania, part of Penn State. Dr. Tsang is also affiliated with NYC Health + Hospitals/Elmhurst. The medical group on file is Penn State Health Medical Group. Dmand AI also links Dr. Tsang to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tsang practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Tsang's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Tsang is licensed in New York.

CMS data shows 1,078 Medicare services from Dr. Tsang across 12 procedure codes in 2024, for 87 Medicare patients. Medicare paid $72,184 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 87 Medicare patients who saw Dr. Tsang in 2024. The largest group is 75 to 84, with 37 patients. 75% of them have cancer, and 75% have high blood pressure. 15% are also on Medicaid. Their average risk score is 1.84, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tsang's median patient age at 71, with 48% women.

In 2024, Dr. Tsang wrote 17 Medicare Part D claims. 100% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $889 in total drug cost. In 2022, CMS named 12 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Tsang for performance year 2024, reported as part of a group. Dr. Tsang accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Tsang to 7 clinical trials, 5 of them phase 3 studies. 7 are still active or recruiting. Conditions studied include Carcinoma, Lobular, Prostatic Neoplasms and Squamous Cell Carcinoma of Head and Neck. NRG Oncology sponsors the most, 3.

CMS Open Payments shows 21 general payments to Dr. Tsang from 12 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 94% of the total. Bristol-Myers Squibb Company paid the most, $237.

Dr. Tsang graduated from Wayne State University School of Medicine in 1998.